.png)
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2027
Published On : November 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC111671
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Cancer Immunotherapy Market By Product (Cancer Vaccines, Oncolytic Viral Therapies, Monoclonal Antibodies and Immunomodulators) and Cancer Type (Pancreatic Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer and Head & Neck Cancer) - Global Industry Analysis And Forecast To 2027
Industry Outlook
Cancer Immunotherapy is a type of treatment that makes use of some parts of person’s immune system to fight the disease. Cancer Immunotherapy works in the following ways; one is stimulating the immune system to work smarter & harder to fight the cancer cells and the other way is providing man-made immune system components to immune system. Immunotherapy is also sometimes called as biotherapy or biologic therapy. Research for newer techniques to immune treatment is done for improving the impact on treatment of cancer in future. Cancer Immunotherapy use is growing owing to; ongoing research in the field of chemo immunotherapy, increasing number of cases related to cancer, technical development in the therapies for treatment, increase in the R&D for treatment of cancer, etc. Therefore, the Cancer Immunotherapy Market is anticipated to expand and has tremendous scope during the forecast period. The global Cancer Immunotherapy Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Cancer Immunotherapy Market is based on segment, by Product the market is segmented into Cancer Vaccines, Oncolytic Viral Therapies, Monoclonal Antibodies and Immunomodulators, and by Cancer Type the market is segmented into Pancreatic Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer and Head & Neck Cancer.
- Cancer Immunotherapy Market, By Product
- Cancer Vaccines
- Oncolytic Viral Therapies
- Monoclonal Antibodies
- Immunomodulators
- Cancer Immunotherapy Market, By Cancer Type
- Pancreatic Cancer
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Head & Neck Cancer
Regional Insights
On a global front, the Cancer Immunotherapy Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Cancer Immunotherapy Market owing to high number of aged population, modern treatments available, increasing cases of disorders, etc.
Cancer Immunotherapy Market, By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Pfizer Inc., Novartis AG, Amgen Inc., Merck and Co. Inc., AstraZeneca, Immunomedics Inc., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company and Advaxis Inc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Pfizer Inc.
- Novartis AG
- Amgen Inc.
- Merck and Co. Inc.
- AstraZeneca
- Immunomedics Inc.
- F. Hoffmann La Roche Ltd.
- Eli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
- Advaxis Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Cancer Immunotherapy Market, By Product, Estimates and Forecast, 2017-2027 ($Million)
o Cancer Vaccines
o Oncolytic Viral Therapies
o Monoclonal Antibodies
o Immunomodulators
o Cancer Immunotherapy Market, By Cancer Type, Estimates and Forecast, 2017-2027 ($Million)
o Pancreatic Cancer
o Lung Cancer
o Melanoma
o Ovarian Cancer
o Prostate Cancer
o Breast Cancer
o Colorectal Cancer
o Head & Neck Cancer
Cancer Immunotherapy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Cancer Immunotherapy Market, By Country
o U.S. Cancer Immunotherapy Market
o Canada Cancer Immunotherapy Market
o Mexico Cancer Immunotherapy Market
o Europe
§ Europe Cancer Immunotherapy Market, By Country
o Germany Cancer Immunotherapy Market
o UK Cancer Immunotherapy Market
o France Cancer Immunotherapy Market
o Russia Cancer Immunotherapy Market
o Italy Cancer Immunotherapy Market
o Rest of Europe Cancer Immunotherapy Market
o Asia-Pacific
§ Asia-Pacific Cancer Immunotherapy Market, By Country
o China Cancer Immunotherapy Market
o Japan Cancer Immunotherapy Market
o South Korea Cancer Immunotherapy Market
o India Cancer Immunotherapy Market
o Southeast Asia Cancer Immunotherapy Market
o Rest of Asia-Pacific Cancer Immunotherapy Market
o South America
§ South America Cancer Immunotherapy Market, By Country
o Brazil Cancer Immunotherapy Market
o Argentina Cancer Immunotherapy Market
o Columbia Cancer Immunotherapy Market
o Rest of South America Cancer Immunotherapy Market
o Middle East and Africa
§ Middle East and Africa Cancer Immunotherapy Market, By Country
o Saudi Arabia Cancer Immunotherapy Market
o UAE Cancer Immunotherapy Market
o Egypt Cancer Immunotherapy Market
o Nigeria Cancer Immunotherapy Market
o South Africa Cancer Immunotherapy Market
o Rest of MEA Cancer Immunotherapy Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Cancer Immunotherapy Market, By Product
5.1. Introduction
5.2. Global Cancer Immunotherapy Revenue and Market Share by Product (2017-2027)
5.2.1. Global Cancer Immunotherapy Revenue and Revenue Share by Product (2017-2027)
5.3. Cancer Vaccines
5.3.1. Global Cancer Vaccines Revenue and Growth Rate (2017-2027)
5.4. Oncolytic Viral Therapies
5.4.1. Global Oncolytic Viral Therapies Revenue and Growth Rate (2017-2027)
5.5. Monoclonal Antibodies
5.5.1. Global Monoclonal Antibodies Revenue and Growth Rate (2017-2027)
5.6. Immunomodulators
5.6.1. Global Immunomodulators Revenue and Growth Rate (2017-2027)
6. Cancer Immunotherapy Market, By Cancer Type
6.1. Introduction
6.2. Global Cancer Immunotherapy Revenue and Market Share by Cancer Type (2017-2027)
6.2.1. Global Cancer Immunotherapy Revenue and Revenue Share by Cancer Type (2017-2027)
6.3. Pancreatic Cancer
6.3.1. Global Pancreatic Cancer Revenue and Growth Rate (2017-2027)
6.4. Lung Cancer
6.4.1. Global Lung Cancer Revenue and Growth Rate (2017-2027)
6.5. Melanoma
6.5.1. Global Melanoma Revenue and Growth Rate (2017-2027)
6.6. Ovarian Cancer
6.6.1. Global Ovarian Cancer Revenue and Growth Rate (2017-2027)
6.7. Prostate Cancer
6.7.1. Global Prostate Cancer Revenue and Growth Rate (2017-2027)
6.8. Breast Cancer
6.8.1. Global Breast Cancer Revenue and Growth Rate (2017-2027)
6.9. Colorectal Cancer
6.9.1. Global Colorectal Cancer Revenue and Growth Rate (2017-2027)
6.10. Head & Neck Cancer
6.10.1. Global Head & Neck Cancer Revenue and Growth Rate (2017-2027)
7. Cancer Immunotherapy Market, By Region
7.1. Introduction
7.2. Global Cancer Immunotherapy Revenue and Market Share by Regions
7.2.1. Global Cancer Immunotherapy Revenue by Regions (2017-2027)
7.3. North America Cancer Immunotherapy by Countries
7.3.1. North America Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
7.3.2. North America Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Cancer Immunotherapy by Countries
7.4.1. Europe Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
7.4.2. Europe Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Cancer Immunotherapy by Countries
7.5.1. Asia-Pacific Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Cancer Immunotherapy by Countries
7.6.1. South America Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
7.6.2. South America Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Cancer Immunotherapy by Countries
7.7.1. Middle East and Africa Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Pfizer Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. Novartis AG
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Amgen Inc.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Merck and Co. Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. AstraZeneca
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. Immunomedics Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. F. Hoffmann La Roche Ltd.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. Eli Lilly and Company
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. Bayer AG
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
8.10. Bristol-Myers Squibb Company
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Revenue and Market Share
8.11. Advaxis Inc.
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Revenue and Market Share
9. Global Cancer Immunotherapy Market Competition, by Manufacturer
9.1. Global Cancer Immunotherapy Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Cancer Immunotherapy Price By Region (2017-2017)
9.3. Top 5 Cancer Immunotherapy Manufacturer Market Share
9.4. Market Competition Trend
10. Cancer Immunotherapy Market Forecast (2017-2027)
10.1. Global Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Cancer Immunotherapy Market Forecast by Regions (2017-2027)
10.2.1. North America Cancer Immunotherapy Market Forecast (2017-2027)
10.2.1.1. United States Cancer Immunotherapy Market Forecast (2017-2027)
10.2.1.2. Canada Cancer Immunotherapy Market Forecast (2017-2027)
10.2.1.3. Mexico Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2. Europe Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.1. Germany Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.2. France Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.3. UK Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.4. Russia Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.5. Italy Cancer Immunotherapy Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3. Asia-Pacific Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.1. China Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.2. Japan Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.3. Korea Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.4. India Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Cancer Immunotherapy Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast (2017-2027)
10.2.4. South America Cancer Immunotherapy Market Forecast (2017-2027)
10.2.4.1. Brazil Cancer Immunotherapy Market Forecast (2017-2027)
10.2.4.2. Argentina Cancer Immunotherapy Market Forecast (2017-2027)
10.2.4.3. Columbia Cancer Immunotherapy Market Forecast (2017-2027)
10.2.4.4. Rest of South America Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5. Middle East and Africa Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.3. Egypt Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.4. Nigeria Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.5. South Africa Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.6. Turkey Cancer Immunotherapy Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Cancer Immunotherapy Market Forecast (2017-2027)
10.3. Cancer Immunotherapy Market Forecast by Product (2017-2027)
10.3.1. Cancer Immunotherapy Forecast by Product (2017-2027)
10.3.2. Cancer Immunotherapy Market Share Forecast by Product (2017-2027)
10.4. Cancer Immunotherapy Market Forecast by Cancer Type (2017-2027)
10.4.1. Cancer Immunotherapy Forecast by Cancer Type (2017-2027)
10.4.2. Cancer Immunotherapy Market Share Forecast by Cancer Type (2017-2027)
11. List of Tables and Figures
Figure United States Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Cancer Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Cancer Immunotherapy Revenue and Revenue Share by Product (2017-2027)
Figure Global Cancer Vaccines Revenue and Growth Rate (2017-2027)
Figure Global Oncolytic Viral Therapies Revenue and Growth Rate (2017-2027)
Figure Global Monoclonal Antibodies Revenue and Growth Rate (2017-2027)
Figure Global Immunomodulators Revenue and Growth Rate (2017-2027)
Table Global Cancer Immunotherapy Revenue and Revenue Share by Cancer Type (2017-2027)
Figure Global Pancreatic Cancer Revenue and Growth Rate (2017-2027)
Figure Global Lung Cancer Revenue and Growth Rate (2017-2027)
Figure Global Melanoma Revenue and Growth Rate (2017-2027)
Figure Global Ovarian Cancer Revenue and Growth Rate (2017-2027)
Figure Global Prostate Cancer Revenue and Growth Rate (2017-2027)
Figure Global Breast Cancer Revenue and Growth Rate (2017-2027)
Figure Global Colorectal Cancer Revenue and Growth Rate (2017-2027)
Figure Global Head & Neck Cancer Revenue and Growth Rate (2017-2027)
Table Global Cancer Immunotherapy Revenue by Regions (2017-2027)
Figure North America Cancer Immunotherapy Growth Rate (2017-2027)
Figure North America Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
Figure North America Cancer Immunotherapy by Countries (2017-2027)
Figure North America Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
Figure United States Cancer Immunotherapy Growth Rate (2017-2027)
Figure United States Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Canada Cancer Immunotherapy Growth Rate (2017-2027)
Figure Canada Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Mexico Cancer Immunotherapy Growth Rate (2017-2027)
Figure Mexico Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Europe Cancer Immunotherapy Growth Rate (2017-2027)
Figure Europe Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
Figure Europe Cancer Immunotherapy by Countries (2017-2027)
Figure Europe Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
Figure Germany Cancer Immunotherapy Growth Rate (2017-2027)
Figure Germany Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure France Cancer Immunotherapy Growth Rate (2017-2027)
Figure France Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure UK Cancer Immunotherapy Growth Rate (2017-2027)
Figure UK Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Russia Cancer Immunotherapy Growth Rate (2017-2027)
Figure Russia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Italy Cancer Immunotherapy Growth Rate (2017-2027)
Figure Italy Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Europe Cancer Immunotherapy Growth Rate (2017-2027)
Figure Rest of Europe Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Asia-Pacific Cancer Immunotherapy Growth Rate (2017-2027)
Figure Asia-Pacific Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
Figure Asia-Pacific Cancer Immunotherapy by Countries (2017-2027)
Figure Asia-Pacific Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
Figure China Cancer Immunotherapy Growth Rate (2017-2027)
Figure China Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Japan Cancer Immunotherapy Growth Rate (2017-2027)
Figure Japan Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Korea Cancer Immunotherapy Growth Rate (2017-2027)
Figure Korea Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure India Cancer Immunotherapy Growth Rate (2017-2027)
Figure India Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Southeast Asia Cancer Immunotherapy Growth Rate (2017-2027)
Figure Southeast Asia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Cancer Immunotherapy Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South America Cancer Immunotherapy Growth Rate (2017-2027)
Figure South America Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
Figure South America Cancer Immunotherapy by Countries (2017-2027)
Figure South America Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
Figure Brazil Cancer Immunotherapy Growth Rate (2017-2027)
Figure Brazil Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Argentina Cancer Immunotherapy Growth Rate (2017-2027)
Figure Argentina Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Columbia Cancer Immunotherapy Growth Rate (2017-2027)
Figure Columbia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of South America Cancer Immunotherapy Growth Rate (2017-2027)
Figure Rest of South America Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Middle East and Africa Cancer Immunotherapy Growth Rate (2017-2027)
Figure Middle East and Africa Cancer Immunotherapy Revenue and Growth Rate (2017-2027)
Figure Middle East and Africa Cancer Immunotherapy by Countries (2017-2027)
Figure Middle East and Africa Cancer Immunotherapy Revenue (Million USD) by Countries (2017-2027)
Figure Saudi Arabia Cancer Immunotherapy Growth Rate (2017-2027)
Figure Saudi Arabia Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Cancer Immunotherapy Growth Rate (2017-2027)
Figure United Arab Emirates Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Egypt Cancer Immunotherapy Growth Rate (2017-2027)
Figure Egypt Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Nigeria Cancer Immunotherapy Growth Rate (2017-2027)
Figure Nigeria Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South Africa Cancer Immunotherapy Growth Rate (2017-2027)
Figure South Africa Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Turkey Cancer Immunotherapy Growth Rate (2017-2027)
Figure Turkey Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Cancer Immunotherapy Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Table Pfizer Inc. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Inc. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck and Co. Inc. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AstraZeneca Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Immunomedics Inc. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann La Roche Ltd. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Eli Lilly and Company Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer AG Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Company Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Advaxis Inc. Cancer Immunotherapy Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Cancer Immunotherapy Market Share by Manufacturer
Figure Global Cancer Immunotherapy Revenue and Market Share by Manufacturer
Table Global Cancer Immunotherapy Price by Region (2017-2017)
Figure Top 5 Cancer Immunotherapy Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Cancer Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2027)
Table Cancer Immunotherapy Market Forecast by Regions (2017-2027)
Figure North America Cancer Immunotherapy Market Forecast (2017-2027)
Figure United States Cancer Immunotherapy Market Forecast (2017-2027)
Figure Canada Cancer Immunotherapy Market Forecast (2017-2027)
Figure Mexico Cancer Immunotherapy Market Forecast (2017-2027)
Figure Europe Cancer Immunotherapy Market Forecast (2017-2027)
Figure Germany Cancer Immunotherapy Market Forecast (2017-2027)
Figure France Cancer Immunotherapy Market Forecast (2017-2027)
Figure UK Cancer Immunotherapy Market Forecast (2017-2027)
Figure Russia Cancer Immunotherapy Market Forecast (2017-2027)
Figure Italy Cancer Immunotherapy Market Forecast (2017-2027)
Figure Rest of Europe Cancer Immunotherapy Market Forecast (2017-2027)
Figure Asia-Pacific Cancer Immunotherapy Market Forecast (2017-2027)
Figure China Cancer Immunotherapy Market Forecast (2017-2027)
Figure Japan Cancer Immunotherapy Market Forecast (2017-2027)
Figure Korea Cancer Immunotherapy Market Forecast (2017-2027)
Figure India Cancer Immunotherapy Market Forecast (2017-2027)
Figure Southeast Asia Cancer Immunotherapy Market Forecast (2017-2027)
Figure Rest of Asia-Pacific Cancer Immunotherapy Market Forecast (2017-2027)
Figure South America Cancer Immunotherapy Market Forecast (2017-2027)
Figure Brazil Cancer Immunotherapy Market Forecast (2017-2027)
Figure Argentina Cancer Immunotherapy Market Forecast (2017-2027)
Figure Columbia Cancer Immunotherapy Market Forecast (2017-2027)
Figure Rest of South America Cancer Immunotherapy Market Forecast (2017-2027)
Figure Middle East and Africa Cancer Immunotherapy Market Forecast (2017-2027)
Figure Saudi Arabia Cancer Immunotherapy Market Forecast (2017-2027)
Figure United Arab Emirates Cancer Immunotherapy Market Forecast (2017-2027)
Figure Egypt Cancer Immunotherapy Market Forecast (2017-2027)
Figure Nigeria Cancer Immunotherapy Market Forecast (2017-2027)
Figure South Africa Cancer Immunotherapy Market Forecast (2017-2027)
Figure Turkey Cancer Immunotherapy Market Forecast (2017-2027)
Figure Rest of Middle East and Africa Cancer Immunotherapy Market Forecast (2017-2027)
Figure Global Cancer Immunotherapy Forecast by Product (2017-2027)
Figure Global Cancer Immunotherapy Market Share Forecast by Product (2017-2027)
Figure Global Cancer Immunotherapy Forecast by Product (2017-2027)
Figure Global Cancer Immunotherapy Forecast by Cancer Type (2017-2027)
Figure Global Cancer Immunotherapy Market Share Forecast by Cancer Type (2017-2027)
Figure Global Cancer Immunotherapy Forecast by Cancer Type (2017-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|